According to the ETF Finder at ETF Channel, BMRN makes up 4.39% of the Biotech ETF (BBH) which is up by about 2.5% on the day Wednesday.
In afternoon trading Wednesday, BMRN was up about 2.1% on the day.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
TheStreet's Adam Feuerstein answers reader questions about Sarepta Therapeutics and its newly approved drug Exondys 51 for Duchenne muscular dystrophy.
The squeeze is on these stocks, and they are poised for volatile moves.
BioMarin (BMRN) stock was trading sharply higher this morning after Pfizer (PFE) beat out Sanofi (SNY) to purchase Medivation (MDVN).